USD 2.08
(-7.79%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 173.75 Million USD | 16.39% |
2022 | 149.28 Million USD | 0.14% |
2021 | 149.08 Million USD | 923.84% |
2020 | 14.56 Million USD | 18.94% |
2019 | 12.24 Million USD | 0.0% |
2018 | - USD | 0.0% |
2017 | - USD | -100.0% |
2016 | 50 Million USD | 0.0% |
2015 | - USD | 0.0% |
2014 | - USD | 0.0% |
2013 | - USD | 0.0% |
2012 | - USD | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q1 | 173.98 Million USD | 0.14% |
2024 Q2 | 174.22 Million USD | 0.14% |
2023 Q2 | 149.38 Million USD | 0.03% |
2023 Q1 | 149.33 Million USD | 0.03% |
2023 Q3 | 173.46 Million USD | 16.12% |
2023 Q4 | 173.75 Million USD | 0.17% |
2023 FY | 173.75 Million USD | 16.39% |
2022 Q2 | 149.18 Million USD | 0.03% |
2022 Q1 | 149.13 Million USD | 0.03% |
2022 FY | 149.28 Million USD | 0.14% |
2022 Q4 | 149.28 Million USD | 0.03% |
2022 Q3 | 149.23 Million USD | 0.03% |
2021 Q4 | 149.08 Million USD | 0.03% |
2021 Q3 | 149.03 Million USD | 0.03% |
2021 FY | 149.08 Million USD | 923.84% |
2021 Q1 | 13.79 Million USD | -5.29% |
2021 Q2 | 148.98 Million USD | 980.36% |
2020 Q1 | 16.7 Million USD | 36.48% |
2020 FY | 14.56 Million USD | 18.94% |
2020 Q2 | 16.01 Million USD | -4.17% |
2020 Q3 | 15.29 Million USD | -4.46% |
2020 Q4 | 14.56 Million USD | -4.82% |
2019 Q4 | 12.24 Million USD | 13.53% |
2019 Q3 | 10.78 Million USD | -4.16% |
2019 Q2 | 11.25 Million USD | -4.03% |
2019 Q1 | 11.72 Million USD | 0.0% |
2019 FY | 12.24 Million USD | 0.0% |
2018 FY | - USD | 0.0% |
2018 Q4 | - USD | 0.0% |
2018 Q3 | - USD | 0.0% |
2018 Q2 | - USD | 0.0% |
2018 Q1 | - USD | 0.0% |
2017 Q3 | 25 Million USD | 0.0% |
2017 FY | - USD | -100.0% |
2017 Q2 | 25 Million USD | -50.0% |
2017 Q1 | 50 Million USD | 0.0% |
2017 Q4 | - USD | -100.0% |
2016 Q3 | 50 Million USD | 0.0% |
2016 Q2 | - USD | 0.0% |
2016 Q4 | 50 Million USD | 0.0% |
2016 FY | 50 Million USD | 0.0% |
2016 Q1 | - USD | 0.0% |
2015 FY | - USD | 0.0% |
2015 Q1 | - USD | 0.0% |
2015 Q4 | - USD | 0.0% |
2015 Q3 | - USD | 0.0% |
2015 Q2 | - USD | 0.0% |
2014 FY | - USD | 0.0% |
2014 Q2 | - USD | 0.0% |
2014 Q3 | - USD | 0.0% |
2014 Q4 | - USD | 0.0% |
2014 Q1 | - USD | 0.0% |
2013 Q3 | - USD | 0.0% |
2013 Q2 | - USD | 0.0% |
2013 Q4 | - USD | 0.0% |
2013 Q1 | - USD | 0.0% |
2013 FY | - USD | 0.0% |
2012 Q4 | - USD | 0.0% |
2012 FY | - USD | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
uniQure N.V. | 130.06 Million USD | -33.589% |
Agios Pharmaceuticals, Inc. | 56.98 Million USD | -204.894% |
Amicus Therapeutics, Inc. | 387.85 Million USD | 55.202% |
Atara Biotherapeutics, Inc. | 45.69 Million USD | -280.262% |
bluebird bio, Inc. | 224.41 Million USD | 22.577% |
Cara Therapeutics, Inc. | 37.07 Million USD | -368.602% |
Imunon, Inc. | 1.13 Million USD | -15150.949% |
Editas Medicine, Inc. | 24.37 Million USD | -612.921% |
IQVIA Holdings Inc. | 12.95 Billion USD | 98.659% |
Mettler-Toledo International Inc. | 1.97 Billion USD | 91.205% |
Myriad Genetics, Inc. | 130.9 Million USD | -32.737% |
Neurocrine Biosciences, Inc. | 258.3 Million USD | 32.732% |
Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -423.415% |
Verastem, Inc. | 40.08 Million USD | -333.451% |
Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 97.84% |
Waters Corporation | 2.3 Billion USD | 92.464% |
Thermo Fisher Scientific Inc. | 31.3 Billion USD | 99.445% |
Biogen Inc. | 7.18 Billion USD | 97.583% |
Nektar Therapeutics | 112.62 Million USD | -54.276% |
Perrigo Company plc | 3.63 Billion USD | 95.217% |
Dynavax Technologies Corporation | 252.41 Million USD | 31.165% |
Illumina, Inc. | 1.48 Billion USD | 88.331% |
Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -5265.014% |
Iovance Biotherapeutics, Inc. | 1 Million USD | -17275.3% |
Unity Biotechnology, Inc. | 23.53 Million USD | -638.149% |
BioMarin Pharmaceutical Inc. | 593.09 Million USD | 70.704% |
Sangamo Therapeutics, Inc. | 33.51 Million USD | -418.434% |
Evolus, Inc. | 120.35 Million USD | -44.362% |
Adicet Bio, Inc. | 17.7 Million USD | -881.489% |
Aclaris Therapeutics, Inc. | 3.07 Million USD | -5552.342% |
Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 93.572% |
Esperion Therapeutics, Inc. | 501.54 Million USD | 65.357% |
FibroGen, Inc. | 89.69 Million USD | -93.711% |
Agilent Technologies, Inc. | 2.73 Billion USD | 93.647% |
OPKO Health, Inc. | 222.03 Million USD | 21.745% |
Homology Medicines, Inc. | 43.17 Million USD | -302.43% |
Geron Corporation | 35.05 Million USD | -395.715% |
Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 92.584% |
Exelixis, Inc. | 189.94 Million USD | 8.524% |
Viking Therapeutics, Inc. | 936 Thousand USD | -18463.355% |
Anavex Life Sciences Corp. | - USD | -Infinity% |
Intellia Therapeutics, Inc. | 96.74 Million USD | -79.595% |
Zoetis Inc. | 6.56 Billion USD | 97.353% |
Axsome Therapeutics, Inc. | 178.07 Million USD | 2.424% |
Abeona Therapeutics Inc. | 4.4 Million USD | -3847.138% |
Vertex Pharmaceuticals Incorporated | 724.7 Million USD | 76.024% |
Kala Pharmaceuticals, Inc. | 34.19 Million USD | -408.198% |
Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 87.592% |
Sarepta Therapeutics, Inc. | 1.13 Billion USD | 84.658% |
Corcept Therapeutics Incorporated | - USD | -Infinity% |
Halozyme Therapeutics, Inc. | 1.49 Billion USD | 88.411% |
Blueprint Medicines Corporation | 610.96 Million USD | 71.561% |
Insmed Incorporated | 1.19 Billion USD | 85.44% |
TG Therapeutics, Inc. | 100.11 Million USD | -73.548% |
Incyte Corporation | 29.16 Million USD | -495.82% |
Emergent BioSolutions Inc. | 446.5 Million USD | 61.086% |